🔗 Share this article

Following a delay and an unusually contentious session, a federal vaccine advisory panel was set to cast ballots on Friday concerning altering the long-held guideline that all newborns be immunized against hepatitis B.

Intense Discussion and a Deferred Vote

The initial day of the meeting on Thursday was defined by heated debate over limiting availability to the hepatitis B vaccine for infants and a choice to delay the ballot by a day to provide committee members extra time to scrutinize the phrasing. The committee, which counsels the national health agency on vaccination protocols, had put off the vote twice in the past.

“Is there any concrete proof of harm of giving this shot before 30 days? Or is this conjecture?” questioned one committee member.

In answer, another participant stated, “There is inadequate data about the prolonged hazard.”

Present Protocol and Possible Consequences

The shot is currently suggested for every newborn within 24 hours of birth to halt contraction of hepatitis B, which can cause serious liver damage. It has been administered to 1.4 billion people for over thirty years.

The Georgia assembly presented no recent proof of harms caused by the vaccine. Specialists note any modification to the present hepatitis B vaccine regimen could have significant and far-reaching consequences for pediatric well-being in the United States.

Panel Composition and New Appointments

The advisory panel can only offer guidance to the head of the CDC. The group's roster has undergone changes recently, with the announcement that the committee’s most recent chair would leave for an formal position and be substituted with a cardiologist who has been skeptical about other immunizations.

The committee includes a number of immunization doubters who are in agreement with a desire to overhaul – and perhaps, in some cases, eliminate – long-established immunization guidelines.